Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Schumer Calls On HHS Head Azar To Resign

Executive Summary

Chuck Schumer, the top Democratic senator, is calling on HHS secretary Alex Azar to resign, accusing him of putting politics over public health.

You may also be interested in...



House COVID Subcommittee Has Questions For Former FDA Commissioner Hahn

The House Select Subcommittee on the Coronavirus Crisis wants more information on attempts by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccines.

Trust Us: Is Pharma’s COVID-19 Vaccine Pledge Convincing?

Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?

$2Bn Golden Egg: 8 Manufacturers Will Share Billions To Make Ventilators For US Govt

Seven companies – GE, Medtronic, ResMed, Hill-Rom, Vyaire, Hamilton Medical and Zoll – will manufacture 64,431 medical ventilators under the Defense Production Act at a cost of more than $1.4bn, the US Department of Health and Human Services said on 13 April. That figure, when combined with the $646.7m recently awarded to Royal Philips to make 45,500 vents, means the US government will spend more than $2bn on the devices.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT142744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel